Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yuan, Xun ^a   Wu, Hua ^a   Xu, Hanxiao ^a   Han, Na ^a   Chu, Qian ^a   Yu, Shiying ^a   Chen, Yuan ^a   Wu, Kongming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DLL3 PROTEIN, HUMAN; HES1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; NOTCH RECEPTOR; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; NOTCH3 PROTEIN, HUMAN; NOTCH3 RECEPTOR; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR HES 1; TUMOR MARKER;

CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; FACTUAL DATABASE; GENETICS; HUMAN; LUNG TUMOR; LYMPH NODE METASTASIS; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; SURVIVAL RATE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; DISEASE PROGRESSION; HOMEODOMAIN PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, NOTCH1; RECEPTOR, NOTCH3; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION FACTOR HES-1;

EID: 84930221762     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10338     Document Type: Article

References (38)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. Ca-Cancer J. Clin. 64, 9-29 (2014).
2. Johnson, D. H., Schiller, J. H. & Bunn, P.J. Recent clinical advances in lung cancer management. J. Clin. Oncol. 32, 973-82 (2014).
3. Hori, K., Sen, A. & Artavanis-Tsakonas, S. Notch signaling at a glance. J. Cell. Sci. 126, 2135-40 (2013).
4. Grabher, C., von, B. H. & Look, A. T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat. Rev. Cancer. 6, 347-59 (2006).
5. Dang, T. P. et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl. Cancer. Inst. 92, 1355-57 (2000).
6. Allen, T. D., Rodriguez, E. M., Jones, K. D. & Bishop, J. M. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 71, 6010-18 (2011).
7. Liu, Y. P. et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 73, 406-16 (2013).
8. Baumgart, A. et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 70, 5368-78 (2010).
9. Cao, H. et al. Down-regulation of Notch receptor signaling pathway induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells. APMIS. 120, 441-50, (2012).
10. Li, L., Sheehan, C. E. & Ross, J. S. Notch signaling in non small cell lung cancers (NSCLC) is associated with squamous diferentiation and favorable clinical outcome. Lab Invest. 89, 356A-356A (2009).
11. Li, Y. et al. Distinct expression profles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies. Biologics. 4, 163-71 (2010).
12. Jiang, P., Cen H. F., Mao, Y., Yuan, X. D. & Wu, B. Study on expression of Notch signal pathway and VEGF in human non-small cell lung cancer. The Chinese Journal of Clinical Pharmacology. 27, 265-67 (2011).
13. Pesch, B. et al. NOTCH1, HIF1A and other cancer-related proteins in lung tissue from uranium miners-variation by occupational exposure and subtype of lung cancer. PLoS One. 7, e45305 (2012).
14. Jiang, X. et al. Expression and signifcance of Notch1, Jagged1 and VEGF in human non-small cell lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32, 1031-36 (2007).
15. Zhang, S. et al. Inhibition of CK2alpha down-regulates Notch1 signaling in lung cancer cells. J. Cell. Mol. Med. 17, 854-62 (2013).
16. Andersen, S. et al. Correlation and coexpression of HIFs and NOTCH markers in NSCLC. Anticancer Res. 31, 1603-06 (2011).
17. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439, 353-57 (2006).
18. Okayama, H. et al. Identifcation of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72, 100-11 (2012).
19. Westhof, B. et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA. 106, 22293-98(2009).
20. Hou, J. et al. Gene expression-based classifcation of non-small cell lung carcinomas and survival prediction. PLoS One. 5, e10312 (2010).
21. Zhu, C. Q. et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol. 28, 4417-24 (2010).
22. Raponi, M. et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 66, 7466-72 (2006).
23. Hassan, K. A. et al. Notch pathway activity identifes cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 19, 1972-80 (2013).
24. Lee, S.M. et al. Expression of Notch 1 and 3 is related to inhibition of lymph node metastasis and progression in non-small cell lung carcinomas. Basic Appl. Pathol. 1, 93-7 (2008).
25. Andersson, E. R. & Lendahl, U. Terapeutic modulation of Notch signaling-are we there yet? Nat. Rev. Drug Discov. 13, 357-78 (2014).
26. Yuan, X. et al. Notch signaling and EMT in non-small cell lung cancer: biological signifcance and therapeutic application. J. Hematol. Oncol. 7, 87 (2014)
27. Ye, YZ. et al. Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med. Oncol. 30, 595 (2013).
28. Shi, C. et al. Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients. Cell Physiol Biochem. 34, 743-52 (2014)
29. Wael, H. et al. Notch1 signaling controls cell proliferation, apoptosis and diferentiation in lung carcinoma. Lung Cancer. 85, 131-40 (2014).
30. Yu, S. et al. Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer. Histol Histopathol. 28, 277-84 (2013).
31. Tang, Y. et al. Rnd3 Regulates Lung Cancer Cell Proliferation through Notch Signaling. PLoS One. 9, e111897 (2014).
32. Luistro, L. et al. Preclinical profle of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efcacy and pharmacodynamic properties. Cancer Res. 69, 7672-80 (2009).
33. Kang, J. H., Lee, E. H., Park, S. W. & Chung, I. Y. MUC5AC expression through bidirectional communication of Notch and epidermal growth factor receptor pathways. J. Immunol. 187, 222-29 (2011).
34. Xie, M., He, C.S., Wei, S.H. & Zhang, L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur. J. Cancer. 49, 3559-72 (2013).
35. Takebe, N., Nguyen, D. & Yang, SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ter. 141 (2), 140-9(2014).
36. Espinoza, I. & Miele, L. Notch inhibitors for cancer treatment. Pharmacol Ter. 139, 95-110(2013).
37. Tierney, J. F., Stewart L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8, 16 (2007).
38. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283, 2008-12 (2000).